drugset / Trial / NCT07689188

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

NCT07689188

Phase 2 Not yet recruiting 10 enrolled Harrison Dermatology
NaSingle-groupOpen-labelTreatment

Summary

This study investigates the efficacy of topical roflumilast foam in patients with HS.

Timeline

Start
2026-08-10
Primary completion
2028-03-10
Completion
2028-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Roflumilast Small molecule 0.3 % Topical